Superior long-term repopulating capacity of G-CSF + Plerixafor-Mobilized blood: Implications for stem cell gene therapy by studies in the Hbbth-3 mouse model

Human Gene Therapy Methods

Volumn 25, Issue 6, 2014, Pages 317-327

  Psatha, Nikoleta ^a,b   Sgouramali, Eleni ^a,b   Gkountis, Antonios ^a,b   Siametis, Athanasios ^a,b   Baliakas, Panayotis ^a,c   Constantinou, Varnavas ^a   Athanasiou, Evangelia ^a   Arsenakis, Minas ^b   Anagnostopoulos, Achilles ^a   Papayannopoulou, Thalia ^d   Stamatoyannopoulos, George ^e   Yannaki, Evangelia ^a  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD150 ANTIGEN; CD48 ANTIGEN; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; DIFFERENTIATION ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HETEROCYCLIC COMPOUND; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL COUNT; CHIMERA; CONTROLLED STUDY; ENGRAFTMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PHENOTYPE; STEM CELL GENE THERAPY; STEM CELL MOBILIZATION; THALASSEMIA; ANIMAL; BETA-THALASSEMIA; CELL CYCLE; CELL SURVIVAL; DISEASE MODEL; GENE VECTOR; GENETICS; GRAFT SURVIVAL; HISTOCOMPATIBILITY; LENTIVIRINAE; MULTIMODALITY CANCER THERAPY; MUTANT MOUSE STRAIN; PROCEDURES; RADIATION CHIMERA; REPORTER GENE; SPLENECTOMY;

MUS;

ANIMALS; ANTIGENS, DIFFERENTIATION; BETA-THALASSEMIA; CELL CYCLE; CELL SURVIVAL; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; GENES, REPORTER; GENETIC VECTORS; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; LENTIVIRUS; MICE; MICE, MUTANT STRAINS; RADIATION CHIMERA; RECOMBINANT PROTEINS; SPLENECTOMY; TRANSPLANTATION CHIMERA;

EID: 84918796288     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2014.005     Document Type: Article

References (53)

1. Ahmed, F., Ings, S.J., Pizzey, A.R., et al. (2004). Impaired bone marrow homing of cytokine-activated CD34 + cells in the NOD/SCID model. Blood 103, 2079-2087.
2. Aiuti, A., Brigida, I., Ferrua, F., et al. (2009). Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID. Immunol. Res. 44, 150-159.
3. Aiuti, A., Biasco, L., Scaramuzza, S., et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151.
4. Bensinger, W., Singer, J., Appelbaum, F., et al. (1993). Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 81, 3158-3163.
5. Bensinger, W.I., Martin, P.J., Storer, B., et al. (2001). Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N. Engl. J. Med. 344, 175-181.
6. Bensinger, W., DiPersio, J.F., and McCarty, J.M. (2009). Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 43, 181-195.
7. Biffi, A., Montini, E., Lorioli, L., et al. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158.
8. Bonig, H., Priestley, G.V., and Papayannopoulou, T. (2006). Hierarchy of molecular-pathway usage in bone marrow homing and its shift by cytokines. Blood 107, 79-86.
9. Boztug, K., Schmidt, M., Schwarzer, A., et al. (2010). Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 363, 1918-1927.
10. Broxmeyer, H.E., Orschell, C.M., Clapp, D.W., et al. (2005). Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201, 1307-1318.
11. Campbell, T.B., and Broxmeyer, H.E. (2008). CD26 inhibition and hematopoiesis: a novel approach to enhance transplantation. Front. Biosci. 13, 1795-1805.
12. Cartier, N., and Aubourg, P. (2010). Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy. Brain Pathol. 20, 857-862.
13. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823.
14. Cavazzana-Calvo, M., Hacein-bey, S., Saint Basile de, G., et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672.
15. Cavazzana-Calvo, M., Payen, E., Negre, O., et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467, 318-322.
16. Christopherson, K.W., Hangoc, G., Mantel, C.R., and Broxmeyer, H.E. (2004). Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 305, 1000-1003.
17. Devine, S.M., Flomenberg, N., Vesole, D.H., et al. (2004). Rapid mobilization of CD34 + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J. Clin. Oncol. 22, 1095-1102.
18. Devine, S.M., Vij, R., Rettig, M., et al. (2008). Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 112, 990-998.
19. DiPersio, J.F., Micallef, I.N., Stiff, P.J., et al. (2009). Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for. J. Clin. Oncol. 27, 4767-4773.
20. Flomenberg, N., Devine, S.M., Dipersio, J.F., et al. (2005). The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 1867-1874.
21. Goldberg, L.R., Dooner, M.S., Johnson, K.W., et al. (2013). The murine long-term multi-lineage renewal marrow stem cell is a cycling cell. Leukemia 1-35.
22. Gothot, A., van der Loo, J.C., Clapp, D.W., and Srour, E.F. (1998). Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in nonobese diabetic/severe combined immune-deficient mice. Blood 92, 2641-2649.
23. Heldal, D., Tjønnfjord, G., Brinch, L., et al. (2000). A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant. 25, 1129-1136.
24. Hübel, K., Liles, W.C., Broxmeyer, H.E., et al. (2004). Leukocytosis and mobilization of CD34 + hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support. Cancer Ther. 1, 165-172.
25. Jetmore, A., Plett, P.A., Tong, X., et al. (2002). Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34 + cells transplanted into conditioned NOD/SCID recipients. Blood 99, 1585-1593.
26. Kiel, M.J., Yilmaz, O.H., Iwashita, T., et al. (2005). SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121, 1109-1121.
27. Kim, C.H., and Broxmeyer, H.E. (1998). In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood 91, 100-110.
28. Kim, I., He, S., Yilmaz, O.H., Kiel, M.J., and Morrison, S.J. (2006). Enhanced purification of fetal liver hematopoietic stem cells using SLAM family receptors. Blood 108, 737-744.
29. Kollet, O., Spiegel, A., Peled, A., et al. (2001). Rapid and efficient homing of human CD34(+)CD38(-/low)CXCR4(+) stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2m(null) mice. Blood 97, 3283-3291.
30. Lapidot, T., Dar, A., and Kollet, O. (2005). How do stem cells find their way home? Blood 106, 1901-1910.
31. Larochelle, A., Krouse, A., Metzger, M., et al. (2006). AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 107, 3772-3778.
32. Liles, W.C., Broxmeyer, H.E., Rodger, E., et al. (2003). Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102, 2728-2730.
33. Ma, Q., Jones, D., and Springer, T.A. (1999). The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 10, 463-471.
34. Marquez-Curtis, L.A., Turner, A.R., Larratt, L.M., et al. (2009). CD34 + cell responsiveness to stromal cell-derived factor-1alpha underlies rate of engraftment after peripheral blood stem cell transplantation. Transfusion 49, 161-169.
35. Mazurier, F., Gan, O.I., McKenzie, J.L., et al. (2004). Lentivectormediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and cultureinduced stem cell impairment. Blood 103, 545-552.
36. Nademanee, A.P., DiPersio, J.F., Maziarz, R.T., et al. (2012). Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biol. Blood Marrow Transplant. 18, 1564-1572.
37. Oguro, H., Ding, L., and Morrison, S.J. (2013). SLAM family markers resolve functionally distinct subpopulations of hematopoietic stem cells and multipotent progenitors. Cell Stem Cell 13, 102-116.
38. Ott, M.G., Schmidt, M., Schwarzwaelder, K., et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401-409.
39. Passegué, E., Wagers, A.J., Giuriato, S., et al. (2005). Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J. Exp. Med. 202, 1599-1611.
40. Peled, A., Petit, I., Kollet, O., et al. (1999). Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283, 845-848.
41. Ringdén, O., Remberger, M., Runde, V., et al. (2000). Faster engraftment of neutrophils and platelets with peripheral blood stem cells from unrelated donors: a comparison with marrow transplantation. Bone Marrow Transplant. 25 Suppl 2, S6-8.
42. Sheridan, W.P., Begley, C.G., Juttner, C.A., et al. (1992). Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339, 640-644.
43. Szilvassy, S.J., Meyerrose, T.E., Ragland, P.L., and Grimes, B. (2001). Homing and engraftment defects in ex vivo expanded murine hematopoietic cells are associated with downregulation of beta1 integrin. Exp. Hematol. 29, 1494-1502.
44. To, L.B., Roberts, M.M., Haylock, D.N., et al. (1992). Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant. 9, 277-284.
45. Voermans, C., Gerritsen, W.R., von dem Borne, A.E., and van der Schoot, C.E. (1999). Increased migration of cord bloodderived CD34 + cells, as compared to bone marrow and mobilized peripheral blood CD34 + cells across uncoated or fibronectin-coated filters. Exp. Hematol. 27, 1806-1814.
46. Voermans, C., Kooi, M., Rodenhuis, S., and Al, E. (2001). In vitro migratory capacity of CD34 + cells is related to hematopoietic recovery after autologous stem cell transplantation. Blood 97, 799-804.
47. Welschinger, R., Liedtke, F., Basnett, J., et al. (2013). Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice. Exp. Hematol. 41, 293-302.e1.
48. Yang, B., Kirby, S., Lewis, J., et al. (1995). A mouse model for β-thalassemia. Proc. Natl. Acad. Sci. USA 92, 11608-11612.
49. Yannaki, E., Psatha, N., Athanasiou, E., et al. (2010). Mobilization of hematopoietic stem cells in a thalassemic mouse model: implications for human gene therapy of thalassemia. Hum. Gene Ther. 21, 299-310.
50. Yannaki, E., Papayannopoulou, T., Jonlin, E., et al. (2012). Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol. Ther. 20, 230-238.
51. Yannaki, E., Karponi, G., Zervou, F., et al. (2013). Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major. Hum. Gene Ther. 24, 852-860.
52. Yong, K.L., Fahey, A., Pizzey, A., and Linch, D.C. (2002). Influence of cell cycling and cell division on transendothelial migration of CD34 + cells. Br. J. Haematol. 119, 500-509.
53. Zufferey, R., Nagy, D., Mandel, R.J., et al. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15, 871-875.